Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mdc3.14216 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Apomorphine for prolonged disorders of consciousness: a multimodal open-label study.
EClinicalMedicine
December 2024
Coma Science Group, GIGA Consciousness, University of Liège, Liège, Belgium.
Background: Apomorphine is a dopaminergic candidate therapy to improve recovery in patients with prolonged disorders of consciousness (PDoC). Behavioural improvements were previously described in non-controlled case series, but its efficacy and neural mechanisms remain largely unknown. This open-label controlled study using multimodal outcome measures investigates the action of apomorphine in severely brain-injured patients.
View Article and Find Full Text PDFArticle Synopsis
- * Data was collected from 37 patients treated between 2011 and 2022, highlighting that half started nocturnal treatment for motor issues, while others suffered from various non-motor symptoms.
- * The findings show 54% of patients maintained treatment by the end, with some discontinuing due to adverse reactions, indicating the treatment's overall effectiveness and safety despite some challenges.
Gender disparity in access to advanced therapies for patients with Parkinson's disease: a retrospective real-word study.
Front Neurol
September 2024
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Background: Gender differences in the access to advanced therapies for Parkinson's disease (PD) are poorly investigated.
Objective: The objective of this study was to investigate the presence of any gender disparity in the access to advanced therapies for PD.
Design: Retrospective study.
Apomorphine Subcutaneous Infusion Likely Induced Acute Thrombocytopenia in a Patient with Parkinson's Disease and Motor Fluctuations.
Mov Disord Clin Pract
September 2024
Parkinson's Disease and Movement Disorders Unit, IRCCS Mondino Foundation, Pavia, Italy.
Subcutaneous foslevodopa in akinetic crisis. A case report from the neurological intensive care unit.
Front Med (Lausanne)
August 2024
Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany.
Introduction: Akinetic crisis is a severe deterioration of motor performance occurring in syndromes with pre- or postsynaptic dopaminergic deficit, necessitating effective dopamine replacement therapy. The subcutaneously applicable levodopa derivative foslevodopa represents a new therapeutic option for patients with advanced Parkinson's disease as a continuous therapy. However, its potential role as a parenteral treatment option for akinetic crisis has not been investigated, yet.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!